EN DE
STOCK COMPARISON

Galderma Group N vs Jiangsu Hengrui Medicine Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how Galderma Group N (GALD) and Jiangsu Hengrui Medicine Co (600276) compare, as of Aug 8, 2026.

As of Aug 8, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: Galderma Group N trades at CHF 178 versus a fair value of CHF 54.75 (-69%), while Jiangsu Hengrui Medicine Co trades at ¥52.11 versus ¥25.94 (-50%).
Galderma Group N
GALD.SW · CHF · Health Care
-69%
upside to fair value
overvalued
PriceCHF 178
Fair ValueCHF 54.75
Quality70/100
Jiangsu Hengrui Medicine Co
600276.SHG · CNY · Health Care
-50%
upside to fair value
overvalued
Price¥52.11
Fair Value¥25.94
Quality59/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Galderma Group NJiangsu Hengrui Medicine Co
Valuation
80.4×P/E (TTM)43.6×
9.26×P/S (TTM)10.84×
5.95×P/B5.76×
44.4×EV/EBITDA33.0×
1.94×PEG0.93×
0.3%Dividend yield0.4%
CHF 0.44Dividend per share¥0.20
Profitability
12%Net margin25%
18%Operating margin32%
8%Return on equity15%
4%Return on assets9%
Growth
25%Revenue growth (YoY)13%
13.4%Avg. growth/yr (3Y)13.9%
Avg. growth/yr (5Y)2.5%
Balance & size
0.32×Debt / equity
$49BMarket cap$52B
healthyGrowth qualityhealthy

Jiangsu Hengrui Medicine Co leads: 2 to 10 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Galderma Group Nof which business quality 66 · market factors 76 Jiangsu Hengrui Medicine Coof which business quality 68 · market factors 42
ProfitabilityMargins and returns on capital today
41
63
Quality GrowthAre margins and returns improving?
68
41
CashflowEarnings quality: real cash, not paper profit
84
82
Fin. StrengthBalance sheet, leverage, solvency risk
63
100
InvestmentDisciplined investing over empire-building
56
27
Low VolatilityCalm price path (market factor)
86
78
MomentumPrice trend over the last 3–12 months (market factor)
66
30
52W MomentumDistance to the 52-week high (market factor)
80
23
Net IssuanceBuybacks instead of dilution
84
64

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Galderma Group N

DCF ModelsCHF 85.76
Earnings-BasedCHF 44.46
Dividend DiscountCHF 3.08
MultiplesCHF 50.65
Asset-BasedCHF 23.28
Growth DCFCHF 92.90
Economic ProfitCHF 30.16
Growth EarningsCHF 63.69

26 of 26 models see the stock below the current price.

Jiangsu Hengrui Medicine Co

DCF Models¥37.11
Earnings-Based¥21.29
Dividend Discount¥3.82
Multiples¥22.37
Asset-Based¥6.44
Growth DCF¥38.47
Economic Profit¥18.21
Growth Earnings¥29.68

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Galderma Group N
Bear CHF 41.06Fair Value CHF 54.75Bull CHF 68.44
CHF 178 = current price (white tick)
Jiangsu Hengrui Medicine Co
Bear ¥19.95Fair Value ¥25.94Bull ¥40.28
¥52.11 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Galderma Group N · Health Care

Quality score70 · Top 25%
Fair value upside-69% · bottom 25%

Jiangsu Hengrui Medicine Co · Health Care

Quality score59 · Top 25%
Fair value upside-50% · below median

Bottom line

As of Aug 8, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: Galderma Group N trades at CHF 178 versus a fair value of CHF 54.75 (-69%), while Jiangsu Hengrui Medicine Co trades at ¥52.11 versus ¥25.94 (-50%).

Galderma Group N has the higher quality score (70/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.